Skip to main content

Advertisement

Table 1 Baseline characteristics of groups 1 & 2; risk factors, tumor characteristics, and treatment

From: Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case–control study

Characteristic Group 1 Group 2
n = 101 n = 22
Age at diagnosis,
(years); ±SD 36.9 ± 5.2 53.1 ± 4.8
Familial cancer
 n (%) 54 (53%) 0
BMI,
 mean; ±SD 27.7 ± 5.3 27.1 ± 4.2
Age at menarche
 mean ± SD 12.3 ± 1.4 12.7 ± 1.3
Parity
 mean ± SD 2.4 ± 1.6 3.6 ± 2.1
 Nuliparous; n (%) 18 (18%) 1 (5%)
Age at first pregnancy
 mean ± SD 21 ± 5.4 23 ± 5.6
 Breastfeeding; n (%) 48/76 (63%) 11/20 (55%)
 Contraceptive use; n (%) 38/97 (39%) 8/20 (40%)
 Smoking; n (%) 17 (17%) 7 (32%)
Histology; n (%)
 Ductal 80/90 (89%) 18/22 (82%)
 Other 10/90 (11%) 4/22 (18%)
Nuclear Grade; n (%)
 2 31/80 (39%) 18/21 (86%)
 3 42/80 (53%) 2/21 (10%)
Stage; n (%)
 0 1/101 (1%) 1. (0)
 I–II 57/101 (56%) 17/22 (77)
 III 39/101 (39%) 5/22 (23)
 IV 4/101 (4%) 0 (0)
T; n (%)
 0–1 29/100 (29%) 11/22 (50)
 2 37/100 (37%) 7/22 (32)
 3 25/100 (25%) 3/22 (14)
 4 9/100 (9%) 1/22 (4)
N; n (%)
 Positive 59/99 (60%) 12/22 (55%)
IHC; n (%)
 ER (+) 52/95 (55%) 22/22 (100%)
 PR (+) 47/95 (49%) 21/22 (95%)
 HER (+) 19/93 (20%) 5/22 (23%)
 Triple negative 30/93 (32%) 0 (0%)
Surgery type; n (%)
 Radical mastectomy 80/99 (81%) 10/22 (45%)
 Breast conservative 18/99 (18%) 12/22 (55%)
Chemotherapy; n (%)
 Neoadjuvant 28/100 (28%) 4/22 (18%)
 Adjuvant 62/100 (62%) 15/22 (68%)
 Anthrac. based 9/62 (15%) 7/15 (40%)
 Anthrac/Taxane. 45/62 (72%) 6/15 (47%)
  1. SD standard deviation, IHC immunohistochemical analysis, ER estrogen receptor, PR progesterone receptor; all means, and proportions were estimated for all the patients in each group, unless otherwise specified in the table